GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (NAS:RIGL) » Definitions » Cyclically Adjusted FCF per Share

Rigel Pharmaceuticals (Rigel Pharmaceuticals) Cyclically Adjusted FCF per Share : $-0.49 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Rigel Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Rigel Pharmaceuticals's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.036. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.49 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 13.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 8.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 11.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Rigel Pharmaceuticals was 28.40% per year. The lowest was 1.10% per year. And the median was 13.35% per year.

As of today (2024-04-29), Rigel Pharmaceuticals's current stock price is $1.07. Rigel Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-0.49. Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Rigel Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Rigel Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.61 -0.75 -0.66 -0.59 -0.49

Rigel Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.59 -0.57 -0.54 -0.52 -0.49

Competitive Comparison of Rigel Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Rigel Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rigel Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.036/129.4194*129.4194
=-0.036

Current CPI (Dec. 2023) = 129.4194.

Rigel Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.190 99.695 -0.247
201406 -0.229 100.560 -0.295
201409 -0.209 100.428 -0.269
201412 -0.173 99.070 -0.226
201503 0.204 99.621 0.265
201506 -0.207 100.684 -0.266
201509 -0.110 100.392 -0.142
201512 -0.156 99.792 -0.202
201603 -0.251 100.470 -0.323
201606 -0.202 101.688 -0.257
201609 -0.239 101.861 -0.304
201612 -0.126 101.863 -0.160
201703 -0.183 102.862 -0.230
201706 -0.159 103.349 -0.199
201709 -0.142 104.136 -0.176
201712 -0.137 104.011 -0.170
201803 -0.160 105.290 -0.197
201806 -0.171 106.317 -0.208
201809 -0.122 106.507 -0.148
201812 0.069 105.998 0.084
201903 -0.006 107.251 -0.007
201906 -0.100 108.070 -0.120
201909 -0.089 108.329 -0.106
201912 -0.061 108.420 -0.073
202003 -0.022 108.902 -0.026
202006 -0.083 108.767 -0.099
202009 -0.116 109.815 -0.137
202012 -0.095 109.897 -0.112
202103 -0.114 111.754 -0.132
202106 0.322 114.631 0.364
202109 -0.061 115.734 -0.068
202112 -0.111 117.630 -0.122
202203 -0.151 121.301 -0.161
202206 -0.075 125.017 -0.078
202209 -0.078 125.227 -0.081
202212 -0.127 125.222 -0.131
202303 -0.110 127.348 -0.112
202306 0.034 128.729 0.034
202309 -0.008 129.860 -0.008
202312 -0.036 129.419 -0.036

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Rigel Pharmaceuticals  (NAS:RIGL) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Rigel Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals (Rigel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Executives
Raul R Rodriguez officer: Sr VP of Bus Dev and Com Ops 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080
David A Santos officer: EVP, Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Wolfgang Dummer officer: EVP & CMO 5491 OPTICAL CT., SAN JOSE CA 95138
Dean L Schorno officer: EVP & Chief Financial Officer 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Raymond J. Furey officer: EVP, GC & Corp Sec 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Alison L. Hannah director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Brian L. Kotzin director RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Nelson Cabatuan officer: Principal Accounting Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Mayer Eldon C. Iii officer: EVP & Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Stacy Markel officer: EVP Human Resources RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080

Rigel Pharmaceuticals (Rigel Pharmaceuticals) Headlines